Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.

Singh D, Beeh KM, Colgan B, Kornmann O, Leaker B, Watz H, Lucci G, Geraci S, Emirova A, Govoni M, Nandeuil MA.

Respir Res. 2019 Aug 9;20(1):180. doi: 10.1186/s12931-019-1142-7.

2.

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.

Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 6;13:3923-3936. doi: 10.2147/COPD.S179293. eCollection 2018.

3.

Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations.

Kardos P, Beeh KM, Sent U, Mueck T, Gräter H, Michel MC.

BMC Pharmacol Toxicol. 2018 Jul 4;19(1):40. doi: 10.1186/s40360-018-0229-y.

4.

Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).

Beeh KM, Emirova A, Prunier H, Santoro D, Nandeuil MA.

Int J Chron Obstruct Pulmon Dis. 2018 May 25;13:1701-1711. doi: 10.2147/COPD.S168493. eCollection 2018.

5.

Correction to: Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis.

Di Marco F, Sotgiu G, Santus P, O'Donnell DE, Beeh KM, Dore S, Roggi MA, Giuliani L, Blasi F, Centanni S.

Respir Res. 2018 Apr 24;19(1):70. doi: 10.1186/s12931-018-0764-5.

6.

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis.

Di Marco F, Sotgiu G, Santus P, O'Donnell DE, Beeh KM, Dore S, Roggi MA, Giuliani L, Blasi F, Centanni S.

Respir Res. 2018 Jan 24;19(1):18. doi: 10.1186/s12931-018-0721-3. Review. Erratum in: Respir Res. 2018 Apr 24;19(1):70.

7.

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.

Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E.

Int J Chron Obstruct Pulmon Dis. 2017 Aug 24;12:2545-2558. doi: 10.2147/COPD.S143488. eCollection 2017.

8.

How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Fležar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Ställberg B, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):139-149. doi: 10.1164/rccm.201609-1794CI. Review.

9.
10.

The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease.

Beeh KM.

Tuberc Respir Dis (Seoul). 2016 Oct;79(4):241-247. Epub 2016 Oct 5. Review.

11.

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).

Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D, Gunstone A, Casamor R, Kostikas K, Aalamian-Mattheis M.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 28;11:1425-34. doi: 10.2147/COPD.S106127. eCollection 2016.

12.

The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).

Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L.

Int J Chron Obstruct Pulmon Dis. 2016 Feb 4;11:193-205. doi: 10.2147/COPD.S95055. eCollection 2016.

13.

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance.

Beeh KM, Kirsten AM, Dusser D, Sharma A, Cornelissen P, Sigmund R, Moroni-Zentgraf P, Dahl R.

J Aerosol Med Pulm Drug Deliv. 2016 Oct;29(5):406-415. Epub 2016 Feb 9.

14.

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.

O'Byrne PM, D'Urzo T, Beck E, Fležar M, Gahlemann M, Hart L, Blahova Z, Toorawa R, Beeh KM.

Respir Res. 2015 Aug 18;16:97. doi: 10.1186/s12931-015-0249-8.

15.
16.

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).

Vogelmeier CF, Asijee GM, Kupas K, Beeh KM.

Adv Ther. 2015 Jun;32(6):537-47. doi: 10.1007/s12325-015-0216-2. Epub 2015 Jun 23.

17.

Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.

Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H.

N Engl J Med. 2015 May 21;372(21):1987-95. doi: 10.1056/NEJMoa1411776. Epub 2015 May 17.

18.

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.

Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.

Pulm Pharmacol Ther. 2015 Jun;32:53-9. doi: 10.1016/j.pupt.2015.04.002. Epub 2015 May 6.

19.

Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD.

Cazzola M, Beeh KM, Price D, Roche N.

Pulm Pharmacol Ther. 2015 Apr;31:68-78. doi: 10.1016/j.pupt.2015.02.007. Epub 2015 Feb 26.

20.

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.

Beeh KM, Watz H, Puente-Maestu L, de Teresa L, Jarreta D, Caracta C, Garcia Gil E, Magnussen H.

BMC Pulm Med. 2014 Dec 23;14:209. doi: 10.1186/1471-2466-14-209.

21.

Longitudinal measurement of airway inflammation over one year in children and adults with intermittent asthma.

Pedersen F, Holz O, Kanniess F, Zielen S, Schulze J, Gillissen A, von Berg A, Berdel D, Beier J, Beeh K, Schnoor M, Magnussen H.

BMC Res Notes. 2014 Dec 17;7:925. doi: 10.1186/1756-0500-7-925.

22.

Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.

Murphy L, Rennard S, Donohue J, Molimard M, Dahl R, Beeh KM, Dederichs J, Fülle HJ, Higgins M, Young D.

Drugs. 2014 Sep;74(14):1635-57. doi: 10.1007/s40265-014-0284-7. Review.

PMID:
25212789
23.

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.

Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Unseld A, Engel M, Korn S.

Respir Res. 2014 Jun 3;15:61. doi: 10.1186/1465-9921-15-61.

24.

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.

Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D.

Respir Med. 2014 Apr;108(4):584-92. doi: 10.1016/j.rmed.2014.01.006. Epub 2014 Jan 21.

25.

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.

Chapman KR, Beeh KM, Beier J, Bateman ED, D'Urzo A, Nutbrown R, Henley M, Chen H, Overend T, D'Andrea P.

BMC Pulm Med. 2014 Jan 17;14:4. doi: 10.1186/1471-2466-14-4.

26.

Minimal clinically important differences in pharmacological trials.

Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA.

Am J Respir Crit Care Med. 2014 Feb 1;189(3):250-5. doi: 10.1164/rccm.201310-1863PP. Review.

PMID:
24383418
27.

"All I want for christmas is two": the advent of novel fixed-combination inhalers for COPD and outlook for 2014.

Beeh KM.

Adv Ther. 2013 Dec;30(12):1033-7. doi: 10.1007/s12325-013-0075-7. Epub 2013 Nov 26. No abstract available.

28.

Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.

Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, Vogelmeier CF.

Respir Res. 2013 Oct 29;14:116. doi: 10.1186/1465-9921-14-116.

29.

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.

Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, Willers J, Stocker H, Mueller P, Bachmann MF, Renner WA.

J Allergy Clin Immunol. 2013 Mar;131(3):866-74. doi: 10.1016/j.jaci.2012.12.1561. Epub 2013 Feb 4.

PMID:
23384679
30.

Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD.

Watz H, Bock D, Meyer M, Schierhorn K, Vollhardt K, Woischwill C, Pedersen F, Kirsten A, Beeh KM, Meyer-Sabellek W, Magnussen H, Beier J.

Pulm Pharmacol Ther. 2013 Apr;26(2):265-70. doi: 10.1016/j.pupt.2012.12.003. Epub 2012 Dec 17.

PMID:
23257347
31.

Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial.

Rabe KF, Fabbri LM, Vogelmeier C, Kögler H, Schmidt H, Beeh KM, Glaab T.

Chest. 2013 Mar;143(3):711-719. doi: 10.1378/chest.12-1277.

PMID:
23188489
32.

Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients.

Vogelmeier C, Fabbri LM, Rabe KF, Beeh KM, Schmidt H, Metzdorf N, Glaab T.

Respir Med. 2013 Jan;107(1):75-83. doi: 10.1016/j.rmed.2012.09.015. Epub 2012 Oct 26.

33.

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.

Beeh KM, Singh D, Di Scala L, Drollmann A.

Int J Chron Obstruct Pulmon Dis. 2012;7:503-13. doi: 10.2147/COPD.S32451. Epub 2012 Jul 31.

34.
35.

Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.

Hoogendoorn M, Al MJ, Beeh KM, Bowles D, Graf von der Schulenburg JM, Lungershausen J, Monz BU, Schmidt H, Vogelmeier C, Rutten-van Mölken MP.

Eur Respir J. 2013 Mar;41(3):556-64. doi: 10.1183/09031936.00027212. Epub 2012 Jun 14.

36.

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.

Beier J, Beeh KM.

Int J Chron Obstruct Pulmon Dis. 2011;6:237-43. doi: 10.2147/COPD.S7371. Epub 2011 Apr 12. Review.

37.

Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.

Beeh KM, Wagner F, Khindri S, Drollmann AF.

COPD. 2011 Oct;8(5):340-5. doi: 10.3109/15412555.2011.594464. Epub 2011 Jul 27.

PMID:
21793716
38.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators.

N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

39.
40.

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.

Beeh KM, Beier J.

Adv Ther. 2010 Mar;27(3):150-9. doi: 10.1007/s12325-010-0017-6. Epub 2010 Apr 19. Review.

PMID:
20411368
41.

Is there a role for antiinflammatory treatment in COPD?

Beeh KM, Glaab T.

COPD. 2009 Oct;6(5):395-403. Review.

PMID:
19863369
42.

Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.

Beeh KM, Beier J.

Adv Ther. 2009 Jul;26(7):691-9. doi: 10.1007/s12325-009-0044-3. Epub 2009 Jul 16. Review. Erratum in: Adv Ther. 2009 Aug;26(8):812. Dosage error in article text.

PMID:
19609496
43.

Bronchodilator effects of indacaterol and formoterol in patients with COPD.

Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S.

Pulm Pharmacol Ther. 2009 Dec;22(6):492-6. doi: 10.1016/j.pupt.2009.05.001. Epub 2009 May 22.

PMID:
19465142
44.

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations.

Beeh KM, Hederer B, Glaab T, Müller A, Rutten-van Moelken M, Kesten S, Vogelmeier C.

Int J Chron Obstruct Pulmon Dis. 2009;4:119-25. Epub 2009 Apr 15.

45.

Antiinflammatory properties of ambroxol.

Beeh KM, Beier J, Esperester A, Paul LD.

Eur J Med Res. 2008 Dec 3;13(12):557-62. Review.

PMID:
19073395
46.

Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease.

Grönke L, Beeh KM, Cameron R, Kornmann O, Beier J, Shaw M, Holz O, Buhl R, Magnussen H, Jörres RA.

Pulm Pharmacol Ther. 2008;21(2):409-17. Epub 2007 Nov 9.

PMID:
18063399
47.

Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.

Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A.

Eur Respir J. 2007 May;29(5):871-8. Epub 2007 Jan 24.

48.

Improvement in quality of life with omalizumab in patients with severe allergic asthma.

Chipps B, Buhl R, Beeh KM, Fox H, Thomas K, Reisner C.

Curr Med Res Opin. 2006 Nov;22(11):2201-8.

PMID:
17076981
49.

Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males.

Meyer M, Beeh KM, Beier J, Beyer D, Aydt E, Zahlten R, Jilma B, Wolff G.

Br J Clin Pharmacol. 2007 Apr;63(4):451-8. Epub 2006 Sep 20.

50.

[Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities].

Beeh KM, Beier J, Buhl R, Stark-Lorenzen P, Gerken F, Metzdorf N; ATEM-Studiengruppe.

Pneumologie. 2006 Jun;60(6):341-6. German.

PMID:
16761228

Supplemental Content

Support Center